Search

Armata Pharmaceuticals and Innoviva have announced a $25 Million investment to support Armata's phage cocktail development.

We've seen Adaptive Phage Therapeutics (APT) in the news a lot lately—here's an interview with Greg Merril, APT's CEO, a podcast interview with a patient whose leg was saved by APT's phages, and a news article on APT's selection for Startup

PhagoMed attended the Biotech Showcase 2020 this week in San Francisco, and announced it is looking to raise $16 million from US and European investors to bring its phage products to the clinic (watch this interview with CEO Alexander Belcr

Adaptive Phage Therapeutics was named one of five biotech companies to watch in 2020 by BioBuzz.

Adaptive Phage Therapeutics was named one of five biotech companies to watch in 2020 by BioBuzz.

PhagoMed attended the Biotech Showcase 2020 this week in San Francisco, and announced it is looking to raise $16 million from US and European investors to bring its phage products to the clinic (watch this interview with CEO Alexander Belcr

Adaptive Phage Therapeutics was awarded a $10.2-million contract with the US Department of Defense. The funds will go toward developing PhageBank™️, the company's personalized phage therapy system, including conducting a clinical trial.

Locus Biosciences announced it has opened enrollment for a Phase 1b clinical trial evaluating a CRISPR Cas3-enhanced phage (crPhage™) product that will target E. coli causing urinary tract infections. This is the world's first controlled cl

Locus Biosciences announced it has opened enrollment for a Phase 1b clinical trial evaluating a CRISPR Cas3-enhanced phage (crPhage™) product that will target E. coli causing urinary tract infections. This is the world's first controlled cl

Adaptive Phage Therapeutics was awarded a $10.2-million contract with the US Department of Defense. The funds will go toward developing PhageBank™️, the company's personalized phage therapy system, including conducting a clinical trial.

Cytophage Technologies is an up and coming phage biotech company out of Winnipeg, Canada: here's an introduction (including how the founder treated his own foot with phages, and plans to start by breaking into the poultry market). News stor

Cytophage Technologies is an up and coming phage biotech company out of Winnipeg, Canada: here's an introduction (including how the founder treated his own foot with phages, and plans to start by breaking into the poultry market). News stor

Sci Phage, a Colombian phage biotech company commercializing a Salmonella phage cocktail for use in chicken farms, is one of three winners of the Latin American startup accelerator program GaneshaLab. GaneshaLab will support winning compani

Sci Phage, a Colombian phage biotech company commercializing a Salmonella phage cocktail for use in chicken farms, is one of three winners of the Latin American startup accelerator program GaneshaLab. GaneshaLab will support winning compani

The 2nd Hanson Wade Bacteriophage Therapy Summit will take place March 24-26, 2020 in Boston. Key speakers include representatives from the FDA and the EMA, as well as leaders of several phage biotech companies.

The Turner lab at Yale has successfully treated 13 patients with phages so far. Now, the team has been awarded support from the Blavatnik Fund, which helps Yale scientists commercialize their discoveries. The support has made it possible fo

The Dutch phage company Micreos has urged members of the European Parliament to support authorization of its product, Listex, saying the EU's public health directorate has failed to appropriately regulate the product (which is intended to t

The Dutch phage company Micreos has urged members of the European Parliament to support authorization of its product, Listex, saying the EU's public health directorate has failed to appropriately regulate the product (which is intended to t

The Turner lab at Yale has successfully treated 13 patients with phages so far. Now, the team has been awarded support from the Blavatnik Fund, which helps Yale scientists commercialize their discoveries. The support has made it possible fo

The not-for-profit healthcare organization Hackensack Meridian Health has invested in the phage biotech company Adaptive Phage Therapeutics (APT). According to APT's CEO, Greg Merril, "The high level of interest from strategic and financial